Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
about
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimatesHeparin versus placebo for non-ST elevation acute coronary syndromesFactor Xa inhibitors for acute coronary syndromesPeriprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventionsNew Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?Oral direct thrombin inhibition: a double-edged sword?Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysisPharmacotherapy in the cardiac catheterization laboratory: evolution and recent developmentsThe REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndromeRisks and Benefits of Thrombolytic, Antiplatelet, and Anticoagulant Therapies for ST Segment Elevation Myocardial Infarction: Systematic ReviewFondaparinux in the management of patients with ST-elevation acute myocardial infarctionManagement of acute coronary syndromes with fondaparinuxProthrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarctionAnticoagulation in the management of non-ST-segment elevation acute coronary syndrome.Beyond heparin and warfarin: the new generation of anticoagulants.Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudinPrimary PCI for acute myocardial infarction in a patient with idiopathic thrombocytopenic purpura. A case report and review of the literature.Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.Fondaparinux: does it cause HIT? Can it treat HIT?Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome.Recent advances in antithrombotic therapy after acute coronary syndrome.Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis.Anticoagulation after anterior myocardial infarction and the risk of stroke.Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary eventsClinical review: bleeding - a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and managementFondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies.Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome.Resolving controversies in hip fracture care: the need for large collaborative trials in hip fracturesAnticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitorsNovel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics.Implications of bleeding in acute coronary syndrome and percutaneous coronary intervention.Percutaneous treatment in acute coronary syndromes.Recent advances in the diagnosis and treatment of acute myocardial infarctionReperfusion for STEMI in current Canadian practice: Are we closing the care gap?Myocardial infarction in the elderly
P2860
Q22242896-C431A31C-CFCA-4878-88E4-DDAF6355AAC8Q24186056-A31268B1-320B-42C7-A2C5-5CC32971566CQ24193744-050460FA-8E03-4E73-B703-547A3D2529ADQ24234760-3DCA0A1D-016E-4343-8611-9A02289E9B40Q26740181-BDE48CB4-8A44-4C8F-9DCF-396C8C28E3BBQ26765488-3B51DFE8-DB74-479E-B7E4-04F877D0F507Q26780154-E692221A-359C-42B0-A01B-F5259659C33DQ26853150-24E15144-8D4A-4144-BB5A-9A1203B2EC0EQ26862694-77E854FB-0A00-46C3-9000-55A1F967E621Q27000201-2179E7B7-1EFC-4EAC-9386-04033365A2B9Q27026079-42A698A8-6469-4DD9-A09C-9B365A8383DDQ28219415-44DD7D36-4517-408D-908D-615A34843CFFQ28219642-1B636E3C-5510-42BA-80AC-270389CA722FQ28220222-E8CCF462-8DEC-4588-B1F8-CBE02939B7E1Q30402038-8B038A90-1A80-4FCA-A310-DC4002D338A9Q33374258-BA739AA0-5A8B-4B06-92F2-B82B8B848C53Q33381356-38CABC6C-1D5D-4F82-9246-0790BD097C49Q33388179-BEBC0D03-2BFA-4FAE-A9F3-C0092A363D8CQ33389966-E2997ACA-B87F-4A1C-AD3D-73B8489ADE13Q33392864-FA8B6806-43B7-4F09-A21A-6EF912091061Q33399580-3D8B05E9-8904-49AD-909B-72D6CC3DF95DQ33403263-6EC67382-827D-4642-A18E-4B2390309228Q33590548-206E1DDA-5B03-4B88-A440-983DB7CD677DQ33651541-02AC81E0-07A8-4DEA-AA50-2FBCE049526FQ33668758-CB75414A-7FAA-456C-B12D-297822B12EA2Q33728256-B160305F-10DE-456D-8F90-8A9A42DC54C5Q33750028-1F1C967D-30D6-42DE-9B95-4915BEDEF8ECQ33797609-9C9CAB4E-3076-4E1D-B566-7CCB3DBFF7D4Q34129340-F2FA2A2D-68E6-4E80-918B-ADC6DBC13174Q34199122-4429D4B1-ED45-4846-800B-C43060335A66Q34487339-2438B645-C808-4E4E-90E4-B82B620EB6A5Q34549913-C5D43C22-AFF1-4F03-AB4C-CDE311B9EECCQ34627780-E7089D9A-1EA8-439E-9720-64B6990655BAQ34651051-B58DF1DF-0604-439E-8871-B4E2AB6B8F5FQ34716730-5F944E24-EE2B-4020-895E-41A8B371CA3CQ35193938-5E4D9BDD-A992-491A-B9B1-3D0F7B9BB6DDQ35510430-69115573-685E-4F7C-88E0-45720F89F09BQ35626702-F9E87203-10FA-4B2A-99D5-8556F99EA44AQ35750305-A100882A-F109-42B0-B9E8-375BDCE3E7CDQ35806730-16D721F4-4BE5-41FD-B96B-EAD036E96384
P2860
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Effects of fondaparinux on mor ...... the OASIS-6 randomized trial.
@en
type
label
Effects of fondaparinux on mor ...... the OASIS-6 randomized trial.
@en
prefLabel
Effects of fondaparinux on mor ...... the OASIS-6 randomized trial.
@en
P2093
P50
P1476
Effects of fondaparinux on mor ...... the OASIS-6 randomized trial.
@en
P2093
Andrzej Budaj
Campbell Joyner
Keith A A Fox
OASIS-6 Trial Group
Rizwan Afzal
Ron J G Peters
Shamir R Mehta
P304
P356
10.1001/JAMA.295.13.JOC60038
P407
P577
2006-03-14T00:00:00Z